These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28622961)

  • 1. ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies.
    Damaj GL; Benbrahim O; Hacini M; Voronina I; Benabed K; Soumoudronga RF; Gasnereau I; Haioun C; Solal-Céligny P
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):362-369.e2. PubMed ID: 28622961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
    Roché H; Eymard JC; Radji A; Prevost A; Diab R; Lamuraglia M; Soumoudronga RF; Gasnereau I; Toledano A
    BMC Cancer; 2018 Nov; 18(1):1127. PubMed ID: 30445935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.
    Nahon S; Rastkhah M; Ben Abdelghani M; Soumoudronga RF; Gasnereau I; Labourey JL
    Support Care Cancer; 2016 May; 24(5):1991-1998. PubMed ID: 26507190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.
    Ludwig H; Gascón P; Bokemeyer C; Aapro M; Boccadoro M; Denhaerynck K; Krendyukov A; MacDonald K; Abraham I
    Support Care Cancer; 2019 Jun; 27(6):2301-2312. PubMed ID: 30343410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
    Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
    Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
    Harbeck N; Gascón P; Krendyukov A; Hoebel N; Gattu S; Blackwell K
    Oncologist; 2018 Apr; 23(4):403-409. PubMed ID: 29317553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.
    Gascón P; Krendyukov A; Höbel N; Aapro M
    Eur J Haematol; 2018 Mar; 100(3):241-246. PubMed ID: 29171913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).
    Bongiovanni A; Monti M; Foca F; Recine F; Riva N; Di Iorio V; Liverani C; De Vita A; Miserocchi G; Mercatali L; Amadori D; Ibrahim T
    Support Care Cancer; 2017 Jan; 25(1):111-117. PubMed ID: 27568305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).
    Aapro M; Bokemeyer C; Ludwig H; Gascón P; Boccadoro M; Denhaerynck K; Gorray M; Krendyukov A; MacDonald K; Abraham I
    J Geriatr Oncol; 2017 Mar; 8(2):86-95. PubMed ID: 27829539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
    Aapro M; Cornes P; Abraham I
    J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.
    Fruehauf S; Otremba B; Stötzer O; Rudolph C
    Adv Ther; 2016 Nov; 33(11):1983-2000. PubMed ID: 27743353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.
    Tesch H; Ulshöfer T; Vehling-Kaiser U; Ottillinger B; Bulenda D; Turner M
    Oncol Res Treat; 2015; 38(4):146-52. PubMed ID: 25877937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.
    Ludwig H; Bokemeyer C; Aapro M; Boccadoro M; Gascón P; Denhaerynck K; Krendyukov A; Abraham I; MacDonald K
    Future Oncol; 2019 Mar; 15(8):897-907. PubMed ID: 30827127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF study.
    Aapro M; Krendyukov A; Höbel N; Gascon P
    Eur J Cancer Care (Engl); 2019 Jul; 28(4):e13034. PubMed ID: 30968997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study.
    Laribi K; Badinand D; Janoray P; Benabed K; Mouysset JL; Fabre E; Monchecourt F; Diab R
    Support Care Cancer; 2019 Nov; 27(11):4283-4292. PubMed ID: 30874925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding 14 days: A French, multicenter, prospective, non-interventional study.
    Phelip JM; Souquet PJ; Hacini M; Chehimi M; Bourgeois V; Bennoune R; Tredan O
    Cancer Treat Res Commun; 2023; 35():100690. PubMed ID: 36780734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study.
    Yousef CC; Khan MA; Almodaimegh H; Alshamrani M; Al-Foheidi M; AlAbdalkarim H; AlJedai A; Naeem A; Abraham I
    J Med Econ; 2023; 26(1):394-402. PubMed ID: 36815700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation.
    Zecchini J; Yum K; Steinberg A; Smith C; Kim S
    Support Care Cancer; 2018 Mar; 26(3):1013-1016. PubMed ID: 28990128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients.
    Hilton J; Vandermeer L; Sienkiewicz M; Mazzarello S; Hutton B; Stober C; Fergusson D; Blanchette P; Joy AA; Brianne Bota A; Clemons M
    Support Care Cancer; 2018 Jul; 26(7):2323-2331. PubMed ID: 29411131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.